Zydus Lifesciences has finalized its acquisition of Assertio Holdings Inc. for USD 166.33 million, making Assertio a wholly-owned subsidiary. The deal bolsters Zydus's U.S. oncology portfolio with Assertio's key drug, ROLVEDON®.

Zydus Lifesciences Acquires Assertio Holdings for USD 166.33 Million

Zydus Lifesciences Limited announced the successful completion of its acquisition of Assertio Holdings Inc. for USD 166.33 million. This transaction officially makes Assertio a wholly-owned subsidiary of Zydus, with Assertio's common stock delisted from the Nasdaq Global Market.

Reader Takeaway: Strategic U.S. oncology expansion with ROLVEDON®; monitor sales growth.

What just happened

Zydus Lifesciences has completed its merger and acquisition of Assertio Holdings Inc. The deal was valued at USD 166.33 million on a fully diluted basis, with an offer price of USD 23.50 per share. Following the transaction, Assertio Holdings Inc. now operates as a wholly-owned subsidiary of Zydus, and its shares have ceased trading on the Nasdaq.

Why this matters

This acquisition significantly strengthens Zydus Lifesciences' footprint in the U.S. specialty oncology market. The primary strategic asset gained is ROLVEDON® (eflapegrastim-xnst), a USFDA-approved biologic used to prevent febrile neutropenia in cancer patients undergoing chemotherapy. Investors will be keen to see how Zydus leverages its commercial capabilities to drive growth for this key product.

The backstory

Assertio Holdings Inc. is a U.S.-based specialty pharmaceutical company focused on oncology. Prior to its acquisition by Zydus, Assertio divested certain products to Cosette Pharmaceuticals Inc. on April 8, 2026. The reported adjusted turnover for the calendar year ended December 31, 2025, of USD 68.23 million, reflects the performance of its main asset, ROLVEDON®.

What changes now

With the completion of the acquisition, Assertio is now fully integrated into Zydus Lifesciences. The company's strategic focus will shift to scaling the ROLVEDON® product within the U.S. oncology supportive care market. Zara Merger Sub Inc., a subsidiary of Zydus, was established specifically for this acquisition and has merged into Assertio.

Risks to watch

While the acquisition is complete, the successful integration and commercialization of ROLVEDON® will be critical. Challenges could arise from market competition, regulatory dynamics, and Zydus's ability to effectively market the product and achieve projected sales growth in the competitive U.S. oncology sector.

Peer comparison

Zydus Lifesciences operates in the broader pharmaceutical sector, competing with other Indian and global companies developing and marketing oncology drugs and supportive care products. Assertio's ROLVEDON® competes in the G-CSF market, facing established players.

Context metrics

• Transaction Value: USD 166.33 million (fully diluted)
• Offer Price: USD 23.50 per share
• Adjusted Turnover (ROLVEDON®) for CY 2025: USD 68.23 million

What to track next

Investors should monitor Zydus Lifesciences' quarterly results for revenue contributions from ROLVEDON® and any management commentary on its market penetration and growth strategies in the U.S. oncology segment.